---
title: Early Warning Scores in Pregnant Woman
nct_id: NCT06488690
overall_status: COMPLETED
phase: NA
sponsor: Suleyman Demirel University
study_type: INTERVENTIONAL
primary_condition: Pregnancy Complications
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06488690.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06488690"
ct_last_update_post_date: 2024-07-05
last_seen_at: "2026-05-12T06:53:40.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Early Warning Scores in Pregnant Woman

**Official Title:** Effectiveness of Early Warning Scores: Preoperative Period in Pregnant Women

**NCT ID:** [NCT06488690](https://clinicaltrials.gov/study/NCT06488690)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 304
- **Lead Sponsor:** Suleyman Demirel University
- **Conditions:** Pregnancy Complications
- **Start Date:** 2022-04-01
- **Completion Date:** 2024-02-01
- **CT.gov Last Update:** 2024-07-05

## Brief Summary

Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.

## Detailed Description

Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.

This prospective study included 304 patients undergoing cesarean section at Suleyman Demirel University between April 2022 and April 2023. Physiological parameters were assessed in all 304 pregnant women before the operation. Maternal early warning scores, including modified early obstetric warning score (MEOWS), maternal early warning score (MEWC), and maternal early warning triggers (MEWT), were calculated for each patient. Patients triggering the system were classified as Group 1 (risky patients), while those not triggering the system were classified as Group 2 (risk-free patients).

## Eligibility

- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* All patients who are pregnant and undergo cesarean section

Exclusion Criteria:

* None
```

## Arms

- **All patients who are pregnant and undergo cesarean section** (OTHER) — We included all patients who were pregnant and underwent cesarean section and calculated maternal early warning scores.

## Interventions

- **All patients who were pregnant and underwent cesarean section** (OTHER) — Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.

## Primary Outcomes

- **MEOWS, MEWC and MEWT scores** _(time frame: One year)_ — The presence of a "trigger" for MEOWS in all systems, defined as either a single severely abnormal parameter (falling in the "red" zone) or two slightly abnormal parameters (falling in the "yellow" zone), was categorized as the risky group. Absence or mildness of the trigger was considered as the risk-free group.
- **MEWC score** _(time frame: One year)_ — In the case of MEWC, the presence of only one abnormal parameter designated the risk group, while the absence of a trigger indicated the risk-free group.
- **MEWT score** _(time frame: One year)_ — For MEWT, the presence of a "trigger" defined as either a single severely abnormal parameter (falling in the "red" zone) or two mildly abnormal parameters (falling in the "yellow" zone) was categorized as the risky group, with the absence or mildness of the trigger considered as the risk-free group.

## Secondary Outcomes

- **APGAR score** _(time frame: One year)_
- **Aldrete score** _(time frame: One year)_
- **Glasgow Coma Scale** _(time frame: One year)_

## Locations (1)

- Suleyman Demirel University, Isparta, Merkez, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.suleyman demirel university|isparta|merkez|turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06488690.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06488690*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*